Pfizer Inc. (NYSE:PFE) Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,973,310 shares of the biopharmaceutical company's stock after purchasing an additional 1,193,722 shares during the period. Schroder Investment Management Group owned approximately 0.18% of Pfizer worth $264,592,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Trading Up 0.2 %

Shares of PFE traded up $0.06 on Wednesday, hitting $24.60. 16,615,305 shares of the stock traded hands, compared to its average volume of 39,123,026. The firm has a market capitalization of $139.52 billion, a P/E ratio of 17.45, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.33 and a 1 year high of $31.54. The stock's 50 day moving average is $26.00 and its two-hundred day moving average is $26.84.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The business's revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.